President Clinton rejected the Medicare reform proposal presented by Sen. John Breaux (D-LA) and his fellow policy makers on the National Bipartisan Commission on the Future of Medicare.
President Clinton rejected the Medicare reform proposal presented by Sen. John Breaux (D-LA) and his fellow policy makers on the National Bipartisan Commission on the Future of Medicare.
"The plan offered by Senator Breaux and his colleagues included some very strong elements, which should be seriously considered by Congress," Clinton said. "However, I believe their approach falls short in several respects."
Among those shortcomings, according to Clinton, are the lack of a prescription drug benefit, the potential to raise premiums for those in the traditional Medicare program, a raise in the age of eligibility for Medicare (from 65 to 67) and no solid commitment to financing a Medicare trust fund.
Clinton said his advisors will draft a plan for Congress to consider. Almost certainly, Clinton's plan will earmark 15% of the federal surplus to a trust fund for Medicare and include a prescription drug benefit. It is unclear, however, whether his plan will include a universal Medicare prescription drug benefit, which some industry experts have predicted could cost the nation more than $30 billion.
Despite Clinton's lack of support, Breaux indicated that he might still introduce Medicare reform legislation for debate this fall. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.